Form 4: Lifecore Biomedical: 22NW Fund, LP Reduces Stake in LFCR
SEC Form 4
Aron R. English, along with related entities, reports the sale of Lifecore Biomedical (LFCR) shares, reducing their holdings.
Summary
- Aron R. English, along with 22NW Fund, LP, 22NW, LP, 22NW Fund GP, LLC, and 22NW GP, Inc., filed a Form 4 detailing changes in beneficial ownership of Lifecore Biomedical, Inc. (LFCR) common stock.
- The report indicates sales of common stock on May 8, 2025, May 9, 2025 and May 12, 2025.
- The sales were executed at weighted average prices of $7.0014, $7.00, and $7.0337 respectively.
- Following these transactions, 22NW Fund, LP indirectly holds 1,662,574 shares of Lifecore Biomedical common stock.
- The reporting persons may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative due to the reduction in holdings by a significant shareholder, which could indicate a lack of confidence or a shift in investment strategy. However, without further context, it's difficult to assess the full impact.
Negatives
- The filing indicates a reduction in the stake held by Aron R. English and related entities in Lifecore Biomedical.
Risks
- Continued selling pressure from major shareholders could negatively impact the stock price.
- The reasons behind the share sales are not disclosed, creating uncertainty.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders or major shareholders trade shares of a publicly traded company. These filings are closely watched by investors for insights into the sentiment and actions of those with the most knowledge of the company.
Stakeholder Impact
- Shareholders may react to the news of the share sales, potentially impacting the stock price.
- The reduced stake could influence investor confidence in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 05/08/2025 | Sale of 5,098 shares at a weighted average price of $7.0014. |
| 05/09/2025 | Sale of 700 shares at $7.00. |
| 05/12/2025 | Sale of 45,698 shares at a weighted average price of $7.0337; Form 4 filing date. |
Keywords
Form 4, Beneficial Ownership, Share Sales, LFCR, Lifecore Biomedical, 22NW Fund, Aron English
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.